Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The FDA in February formally declared the end of the semaglutide shortage, which Novo Nordisk expects will help improve the ...

Available by prescription (Xenical) and over the counter (Alli), it is often used with a low-fat diet. While effective, ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025. | As ...

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be ...

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...